Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA CV Requirements Sideline Sanofi’s Lixisenatide

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Sanofi will withdraw its NDA for the GLP-1 agonist for diabetes to await the final results of an ongoing cardiovascular outcomes trial. The decision could delay a U.S. launch of lixisenatide by three years.

You may also be interested in...



On The Wings Of Lantus: Sanofi Sees Clearer Skies Ahead In Diabetes

With the removal of a near-term competitive threat to Sanofi’s hallmark insulin franchise, 2013 is poised to be a momentum-building year for the big pharma, and more specifically, its diabetes business. The opportunity can’t come too soon, as the company launches the GLP-1 agonist Lyxumia into a crowded and fiercely competitive field.

Drugs From Bausch, J&J And Amgen Top ICER's Unsupported Price Increase List

Seven of the top 10 drugs with net price increases in 2021 that had a substantial effect on US spending did not have adequate new evidence to support any price increase, ICER determined.

Optum Rx Reveals Humira Biosimilar Plan To ‘Support Advancement Of The Market’

United Health's pharmacy benefit manager outlined plans for early inclusion of up to three biosimilar versions of adalimumab on its formularies in 2023, at parity to the brand.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS005241

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel